Vascular events with selective COX2 inhibitors and NSAIDs: analyzing the risks
James M Brophy
Correspondence Royal Victoria Hospital, Ross 4.12, 687 Pine Avenue West, Montreal, QCH3A 1A1, Canada
Email james.brophy@mcgill.ca
This article has no abstract so we have provided the first paragraph of the full text.
The authors of this study are to be commended for their exhaustive meta-analysis; however, several points remain to be considered. Overall study quality could have been improved by following the QUOROM guidelines1 for meta-analyses more closely. Furthermore, a funnel plot to assess the possibility of additional unpublished data and a better description of the process of validating data acquisition and entry would have been useful. Although the statistical model that pools all COX2 inhibitors into one group is justified by testing for statistical heterogeneity, it has low statistical power. Consequently, absence of proof of a difference between COX2 inhibitors does not prove the absence of a difference.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
